Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
Date:2/24/2011

NANJING, China, Feb. 24, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2010 on Tuesday, March 8, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, March 8 at 9 p.m. Beijing/Hong Kong time).To access the conference call, please dial:United States toll-free:

+1.866.831.5605International:

+1.617.213.8851China Telecom:

10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490China Netcom:

10.800.852.1490 / 10.800.712.2655China 400 (for mobile users)

400.881.1630 / 400.881.1629Hong Kong:

+852.3002.1672Please ask to be connected to Q4 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 56440566

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.888.286.8010 International:

+1.617.801.6888The passcode for replay participants is: 22405893.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:
Email: ir@simcere.comIn Nanjing:

Yehong Zhang
President
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8811In the United States:

Kate Tellier
Brunswick Group
Tel: 1-212-333-3810In Beijing:
Ruirui Jiang
Brunswick Group
Tel: 86-10-5960-8600In Hong Kong:
Joseph Lo Chi-Lun
Brunswick Group
Tel: 852-3512-5000
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
2. Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
3. Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
4. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
5. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
6. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
8. Simceres Diosmectite API Passes EU-GMP Inspection
9. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
11. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Australia Ophthalmic Lasers Market Outlook to ... Lasers Market Outlook to 2022", provides key market data ... value, in millions of US dollars, volume (in units) ... Lasers, Femtosecond Lasers and YAG Lasers. The report ... each of these market segements, and global corporate-level profiles ...
(Date:12/8/2016)... Global Interventional Radiology Market: Scope and ... radiology market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/8/2016)... -- Allergy Diagnostics Market: Scope and Methodology ... used to determine the presence of allergens such ... in the samples by determining the presence of ... on global allergy diagnostics market, analyzes the current ... consists of an executive summary that provides information ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... ... 10th anniversary with the grand opening of the Sober College Robert Pfeifer Memorial ... two days, December 2-3, and was attended by an overwhelming amount of alumni, ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... , ... With the increasing demand for dental implants, the National Association of ... inform dentists and patients about the safety issues related to dental restorations. According to ... U.S. is projected to reach $6.4 billion in 2018 with more than 30 million ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):